Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report.
A 4-month-old boy was diagnosed with Kawasaki disease. The ordinary treatments with intravenous gammaglobulin and metylpredonisolone were not effective. Infliximab (5 mg/kg) was administrated on 13th day of illness which led to defeverscence and improvement of clinical manifestations. On 23 days of illness, however, desquamative papules and plaques developed on both the extensor surfaces of the forearms and legs. In addition, typical subungual desquamations of fingers and toes followed crusted hyperkeratosis which resembled supprative acrodermatitis. Skin biopsy from the forearm showed inflammatory dyskeratosis with marked hyperkeratosis, epithelial parakeratotsis, loss of granular layer and dominant infiltration of CD8 + T-cells. Local treatment of steroid followed improvement of skin lesions within a few weeks.


CONCLUSIONS
Although previous reports described the beneficial effects of infliximab in patients with Kawasaki disease, it is possible that the administration of infliximab modify psoriasiform skin lesion associated with Kawasaki disease.
Kishimoto
S
S
Division of Pediatrics, Kyushu Koseinenkin Hospital, Japan.
Muneuchi
J
J
Takahashi
Y
Y
Izu
K
K
Nakano
R
R
Joo
K
K
D000169:Acrodermatitis / Q000175:diagnosis / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005542:Forearm / Q000473:pathology; D006801:Humans; D007223:Infant; D000069285:Infliximab; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000188:drug therapy*; D011565:Psoriasis / Q000175:diagnosis / Q000209:etiology*
D000911:Antibodies, Monoclonal; D000069285:Infliximab